Literature DB >> 10482961

Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling.

M G Ausems1, J Verbiest, M P Hermans, M A Kroos, F A Beemer, J H Wokke, L A Sandkuijl, A J Reuser, A T van der Ploeg.   

Abstract

Glycogen storage disease type II (GSD H) is an autosomal recessive myopathy. Early and late-onset phenotypes are distinguished - infantile, juvenile and adult. Three mutations in the acid alpha-glucosidase gene are common in the Dutch patient population: IVS1(-13T-->G), 525delT and delexon18. 63% of Dutch GSD II patients carry one or two of these mutations, and the genotype-phenotype correlation is known. To determine the frequency of GSD II, we have screened an unselected sample of neonates for the occurrence of these three mutations. Based on the calculated carrier frequencies, the predicted frequency of the disease is 1 in 40000 divided by 1 in 138 000 for infantile GSD II and 1 in 57 000 for adult GSD II. This is about two to four times higher than previously suggested, which is a reason to become more familiar with the presentation of GSD II in its different clinical forms and to adjust the risk assessment for genetic counselling.

Entities:  

Mesh:

Year:  1999        PMID: 10482961     DOI: 10.1038/sj.ejhg.5200367

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  76 in total

Review 1.  Glycogen storage disease type II: clinical overview.

Authors:  M Di Rocco; D Buzzi; M Tarò
Journal:  Acta Myol       Date:  2007-07

2.  Immune Modulation Therapy in a CRIM-Positive and IgG Antibody-Positive Infant with Pompe Disease Treated with Alglucosidase Alfa: A Case Report.

Authors:  Josko Markic; Branka Polic; Radenka Kuzmanic-Samija; Eugenija Marusic; Luka Stricevic; Vitomir Metlicic; Julije Mestrovic
Journal:  JIMD Rep       Date:  2011-09-06

3.  Diffuse cerebral microhemorrhages in a patient with adult-onset Pompe's disease: a case report.

Authors:  Divyajot Sandhu; Adam Rizvi; Jae Kim; Rwoof Reshi
Journal:  J Vasc Interv Neurol       Date:  2014-12

Review 4.  Molecular genetics of Pompe disease: a comprehensive overview.

Authors:  Paolo Peruzzo; Eleonora Pavan; Andrea Dardis
Journal:  Ann Transl Med       Date:  2019-07

Review 5.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

6.  Isolated elevated serum transaminases leading to the diagnosis of asymptomatic Pompe disease.

Authors:  Marieke Hoeksma; Maartje Boon; Klary E Niezen-Koning; Lidy van Overbeek-van Gils; Francjan J van Spronsen
Journal:  Eur J Pediatr       Date:  2006-10-17       Impact factor: 3.183

7.  Comparison of EQ-5D and SF-6D utilities in Pompe disease.

Authors:  T A Kanters; W K Redekop; M E Kruijshaar; A T van der Ploeg; M P M H Rutten-van Mölken; L Hakkaart
Journal:  Qual Life Res       Date:  2014-10-24       Impact factor: 4.147

8.  Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease.

Authors:  Mari Mori; Gloria Haskell; Zoheb Kazi; Xiaolin Zhu; Stephanie M DeArmey; Jennifer L Goldstein; Deeksha Bali; Catherine Rehder; Elizabeth T Cirulli; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-10-17       Impact factor: 4.797

9.  Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.

Authors:  Priya S Kishnani; Paula C Goldenberg; Stephanie L DeArmey; James Heller; Danny Benjamin; Sarah Young; Deeksha Bali; Sue Ann Smith; Jennifer S Li; Hanna Mandel; Dwight Koeberl; Amy Rosenberg; Y-T Chen
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

10.  Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease.

Authors:  Michael Beck
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.